# US 2018/0024143 A1 · Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0024143 A1
- Document ID: US20180024143A1
- Status: Published application
- Kind: A1
- Application number: 15/722,182
- Filed: 2017-10-02
- Published: 2018-01-25
- Earliest claimed: 2009-10-29
- Assignees: True Health IP LLC
- Applicants: True Health IP LLC
- Inventors: Michael P. McKenna; Steven M. Watkins
- Web page: https://patentgrep.com/patent/US20180024143A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- G01N 33/66: involving blood sugars, e.g. galactose
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G16H 50/50: for simulation or modelling of medical disorders
- G16Z 99/00: Subject matter not provided for in other main groups of this subclass
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- G01N 2800/50: Determining the risk of developing a disease
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16Z: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.

## Claims

### Claim 1

A method of evaluating risk for developing a diabetic condition, the method comprising:
(a) obtaining biomarker measurement data for an individual, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual; wherein said biomarkers comprise: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2; and
(b) evaluating risk for the individual developing a diabetic condition based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data.

### Claim 2 (depends on 1)

The method of claim 1, wherein the obtaining step comprises measuring the biomarkers in the at least one biological sample.

### Claim 3 (depends on 2)

The method of claim 2, further comprising a step, prior to the measuring the biomarkers, of obtaining at least one biological sample from the individual.

### Claim 4 (depends on 1)

The method of claim 1, wherein obtaining biomarker measurement data comprises obtaining data representative of a measurement of the level of at least one biomarker from a preexisting record.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the evaluating step includes comparing the biomarker measurement data from the individual with biomarker measurement data of the same biomarkers from a population, and evaluating risk for the individual developing a diabetic condition from the comparison.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, further comprising displaying the risk evaluation from (b) on a visual display.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, further comprising printing or storing the risk evaluation on paper or an electronic storage medium.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, further comprising advising said individual or a health care practitioner of said risk evaluation.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, further comprising:
obtaining clinical measurement data for the individual for at least one clinical parameter selected from the group consisting of age, body mass index (BMI), diastolic blood pressure (DBP), family history (FHX), past gestational diabetes mellitus (GDM), height (HT), hip circumference (Hip), race, sex, systolic blood pressure (SBP), waist circumference (Waist), and weight (WT),
wherein the model is executed based on an input of the biomarker measurement data and the clinical measurement data.

### Claim 10

A method of evaluating risk for developing a diabetic condition, the method comprising:
(a) obtaining measurements of biomarkers from at least one biological sample isolated from an individual, wherein said biomarkers comprise: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2; and
(b) calculating a risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements of biomarkers, and wherein said model was developed by fitting data from a longitudinal study of a population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals.

### Claim 11 (depends on 10)

The method of claim 10, wherein the obtaining step comprises measuring the biomarkers in the at least one biological sample.

### Claim 12 (depends on 10, 11)

The method of claim 10 or 11, further comprising displaying the calculated risk from (b) on a visual display.

### Claim 13 (depends on 10, 11, 12)

The method of any one of claims 10 to 12, further comprising printing or storing the calculated risk on paper or an electronic storage medium.

### Claim 14 (depends on 10, 11, 12, 13)

The method of any one of claims 10 to 13, further comprising advising said individual or a health care practitioner of said risk evaluation.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The method of any one of claims 10 to 14, further comprising:
obtaining at least one clinical measurement for the individual for at least one clinical parameter selected from the group consisting of age, body mass index (BMI), diastolic blood pressure (DBP), family history (FHX), past gestational diabetes mellitus (GDM), height (HT), hip circumference (Hip), race, sex, systolic blood pressure (SBP), waist circumference (Waist), and weight (WT),
wherein the inputs to the model further comprise said at least one clinical measurement.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15, wherein the individual has not been previously diagnosed as having Diabetes, pre-Diabetes, or a pre-diabetic condition.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15, wherein the individual has a pre-diabetic condition, and the method evaluates or calculates risk for the individual developing Diabetes.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 to 17, wherein the individual is pregnant.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to any one of claims 1 to 18, wherein the diabetic condition is selected from the group consisting of Type 2 Diabetes, pre-Diabetes, Metabolic Syndrome, Impaired Glucose Tolerance, and Impaired Fasting Glycemia.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method according to any one of claims 1 to 19, wherein said at least one biological sample comprises whole blood, serum, or plasma.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method according to any one of claims 1 to 20, wherein at least one of said biomarker measurements is obtained by a method selected from the group consisting of immunoassay and enzymatic activity assay.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method according to any one of claims 1 to 21, wherein the method using said biomarkers has an area under the ROC curve, reflecting the degree of diagnostic accuracy for predicting development of the diabetic condition, of at least 0.75, 0.76, 0.77, 0.78, 0.79, 0.80, 0.81, 0.82, 0.83, 0.84, or 0.85.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method according to any one of claims 1 to 22, wherein the method using said biomarkers has an area under the ROC curve, reflecting the degree of diagnostic accuracy for predicting development of the diabetic condition, of at least 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, or 0.15 greater than a corresponding method wherein the biomarkers consist of the glucose and the protein biomarkers but not the lipid metabolites.

### Claim 24

A kit comprising reagents for measuring a group of biomarkers, wherein the biomarkers are:
(i) glucose,
(ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and
(iii) at least one lipid metabolite selected from the lipid metabolites in Table 2.

### Claim 25 (depends on 24)

The kit of claim 24, wherein at least one of the reagents comprises a detectable label.

### Claim 26 (depends on 24)

The kit of claim 24, wherein the reagents for the protein biomarkers and lipid metabolites are attached to a solid support.

### Claim 27

A computer readable medium having computer executable instructions for evaluating risk for developing a diabetic condition, the computer readable medium comprising:
a routine, stored on the computer readable medium and adapted to be executed by a processor, to store biomarker measurement data representing measurements of at least the following: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2; and
a routine stored on the computer readable medium and adapted to be executed by a processor to analyze the biomarker measurement data to evaluate a risk for developing a diabetic condition.

### Claim 28

A medical diagnostic test system for evaluating risk for developing a diabetic condition, the system comprising:
a data collection tool adapted to collect biomarker measurement data representative of measurements of biomarkers in at least one biological sample from an individual, wherein said biomarkers comprise: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2; and
an analysis tool comprising a statistical analysis engine adapted to generate a representation of a correlation between a risk for developing a diabetic condition and
measurements of the biomarkers, wherein the representation of the correlation is adapted to be executed to generate a result; and
an index computation tool adapted to analyze the result to determine the individual's risk for developing a diabetic condition and represent the result as an index value.

### Claim 29 (depends on 28)

The medical diagnostic test system of claim 28, wherein the analysis tool comprises a first analysis tool comprising a first statistical analysis engine, the system further comprising a second analysis tool comprising a second statistical analysis engine adapted to select the representation of the correlation between the risk for developing a diabetic condition and measurements of the biomarkers from among a plurality of representations capable of representing the correlation.

### Claim 30 (depends on 28, 29)

The system of claim 28 or 29, further comprising a reporting tool adapted to generate a report comprising the index value.

### Claim 31

A method of developing a model for evaluation of risk for developing a diabetic condition, the method comprising:
obtaining biomarker measurement data, wherein the biomarker measurement data is representative of measurements of biomarkers from a population and includes endpoints of the population; wherein said biomarkers for which measurement data is obtained comprise: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2;
inputting the biomarker measurement data of at least a subset of the population into a model; and
training the model for endpoints using the inputted biomarker measurement data to derive a representation of a correlation between a risk of developing a diabetic condition and measurements of biomarkers in at least one biological sample from an individual.

### Claim 32

A method of evaluating the current status of a diabetic condition in an individual, the method comprising:
obtaining biomarker measurement data, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual, wherein said biomarkers comprise: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2; and
evaluating the current status of a diabetic condition in the individual based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data.

### Claim 33

A method of evaluating a diabetic disease surrogate endpoint an individual, the method comprising:
obtaining biomarker measurement data, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual; wherein said biomarkers comprise: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2; and
evaluating a diabetic disease surrogate endpoint in the individual based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, kit, computer readable medium, or system of any one of claims 1 to 33, wherein said biomarkers comprise at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten protein biomarkers from Table 1.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, kit, computer readable medium, or system of any one of claims 1 to 33, wherein said at least three protein biomarkers are selected from the group consisting of adiponectin, C-reactive protein (CRP), HbAlc, IGFBPI, IGFBP2, Insulin, IL2RA, ferritin, and LEP.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, kit, computer readable medium, or system of any one of claims 1 to 33, wherein said at least three protein biomarkers are selected from the group consisting of: adiponectin, C-reactive protein (CRP), IL2RA, ferritin, insulin, and HbAlc.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, kit, computer readable medium, or system of any one of claims 1 to 33, wherein said at least three protein biomarkers include at least one glycemic index marker selected from insulin and HbAlc.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, kit, computer readable medium, or system of any one of claims 1 to 33, wherein said at least three protein biomarkers comprise adiponectin, insulin, and C-reactive protein.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, kit, computer readable medium, or system of any one of claims 1 to 33, wherein said at least three protein biomarkers adiponectin, CRP and HbAlc

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method, kit, computer readable medium, or system of any one of claims 1 to 33, wherein said at least three protein biomarkers are selected from the combinations of any one of FIGS. 8-26.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method, kit, computer readable medium, or system of any one of claims 1 to 40, wherein said at least three protein markers and at least one lipid metabolite are selected from the combinations of any one of FIGS. 27-35.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method, kit, computer readable medium, or any system of any one of claims 1-41, wherein said biomarkers comprise at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten lipid metabolites from Table 2.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises at least one cholesterol ester.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises at least one lipid metabolite selected from the group consisting of AC6:0, AC8:0, AC10:0, CE16:0, CE16:ln7, CE18:0, CE18:3n6, CE18:ln9, CE 18:2n6, CE20:3n6, CE20:4n3, TGTL, DG16:0, DG18:0, DG18:ln9, DG18:2n6, DG18:3n3, DGTL, FA16:0, FA16:ln7, FA18:ln9, FA18:2n6, FA24:0, LY16:ln7, LY18:ln7, LY18:ln9, LY18:2n6, PC16:ln7, PC18:2n6, PC18:3n6, PC18:ln7, PC20:3n9, PC22:4n6, PC22:5n3, PCdml8:0, PCdml8:ln9, PCdml6:0, PC20:3n6, PC20:4n3, PEdm18:ln9, PE16:ln7, PE18:2n6, PE20:2n6, PE22:0, PE24:ln9 PEdml8:0, TG16:0, TG16:ln7, TG18:0, TG18:ln7, TG18:ln9, TG18:2n6 and TG18:3n3.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite selected from the group consisting of CE16:ln7, CE20:3n6, CE18:2n6, CE16:0, CE18:ln9, LY18:2n6, LY18:ln7 and LY18:ln9.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises CE 16:ln7.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises CE 20:3n6.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises CE18:2n6.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises CE16:0.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises CE18:ln9.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises LY18:2n6.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method, kit, computer readable medium, or system of any one of claims 1 to 42, wherein said at least one lipid metabolite comprises LY18:ln7 or LY18:ln9.

### Claim 53 (depends on 2)

A method of prophylaxis for Diabetes comprising:
obtaining risk score data representing a Diabetes risk score for an individual, wherein the Diabetes risk score is computed according to the method of claim 2 for calculating a risk of developing a diabetic condition; and
generating prescription treatment data representing a prescription for a treatment regimen to delay or prevent the onset of Diabetes to an individual identified by the Diabetes risk score as being at elevated risk for Diabetes.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

A method of prophylaxis for Diabetes comprising:
evaluating or calculating risk, for at least one subject, of developing a diabetic condition according to the method of any one of claims 1-23 and 34-52; and
treating a subject identified as being at elevated risk for a diabetic condition with a treatment regimen to delay or prevent the onset of Diabetes.

### Claim 55 (depends on 53, 54)

The method according to claim 53 or 54, wherein the treatment regimen comprises at least one therapeutic selected from the group consisting of: INS, INS analogs, hypoglycemic agents, anti-inflammatory agents, lipid-reducing agents, calcium channel blockers, beta-adrenergic receptor blocking agents, cyclooxygenase-2 (COX-2) inhibitors, prodrugs of COX-2 inhibitors, angiotensin II antagonists, angiotensin converting enzyme (ACE) inhibitors, renin inhibitors, lipase inhibitors, amylin analogs, sodium-glucose cotransporter 2 inhibitors, dual adipose triglyceride lipase and PI3 kinase activators, antagonists of neuropeptide Y receptors, human hormone analogs, cannabinoid receptor antagonists, triple monoamine oxidase reuptake inhibitors, inhibitors of norepinephrine and dopamine reuptake, inhibitors of 11 Beta-hydroxysteroid dehydrogenase type 1 (I lb-HSDI), inhibitors of Cortisol synthesis, inhibitors of gluconeogenesis, glucokinase activators, antisense inhibitors of protein tyrosine phosphatase-IB, islet neogenesis therapy, and betahistine.

### Claim 56 (depends on 53, 54)

The method according to claim 53 or 54, wherein the treatment region comprises at least one therapeutic at least one therapeutic selected from the group consisting of acarbose, metformin, troglitazone, and rosightazone.

### Claim 57 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method of ranking or grouping a population of individuals, comprising:
calculating for developing a diabetic condition according to the method of any one of claims 10 to 23 for individuals comprised within the population; and
ranking individuals within the population relative to the remaining individuals in the population or dividing the population into at least two groups, based on factors comprising said risk for developing a diabetic condition.

### Claim 58 (depends on 57)

The method of claim 57, further comprising using ranking data representing the ranking or grouping of the population of individuals for one or more of the following purposes:
to determine an individual's eligibility for health insurance;
to determine an individual's premium for health insurance;
to determine an individual's premium for membership in a health care plan, health maintenance organization, or preferred provider organization; and
to assign health care practitioners to an individual in a health care plan, health maintenance organization, or preferred provider organization.

### Claim 59 (depends on 57, 58)

The method of claim 57 or 58, further comprising using ranking data representing the ranking or grouping of the population of individuals for one or more purposes selected from the group consisting of:
to recommend therapeutic intervention or lifestyle intervention to an individual or group of individuals;
to manage the health care of an individual or group of individuals;
to monitor the health of an individual or group of individuals; and
to monitor the health care treatment, therapeutic intervention, or lifestyle intervention for an individual or group of individuals.

### Claim 60

A method of evaluating the current status of a diabetic condition in an individual, the method comprising:
obtaining biomarker measurement data, wherein the biomarker measurement data is representative of measurements of biomarkers in at least one biological sample from the individual; and
evaluating the current status of a diabetic condition in the individual based on an output from a model, wherein the model is executed based on an input of the biomarker measurement data;
wherein said biomarkers comprise: (i) glucose, (ii) at least three protein biomarkers selected from the protein biomarkers in Table 1 and (iii) at least one lipid metabolite selected from the lipid metabolites in Table 2.
